The development of antibodies and associated technologies continues to drive high-value deals, according to a recent report in Nature.1 Using data provided by DealForma for the period 1 January 2022 to 16 June 2023, Nature analysed the deal trends in the field. In 2022, there were 156 antibody-focused deals with a value of $57.3 billion, […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!